3B BlackBio Dx diagnostic kits revenue reaches Rs 45.02 crore

3B BlackBio Dx Limited reported diagnostic-kits revenue of Rs 45.02 crore for the quarter ended September 30, 2026, up from Rs 30.43 crore a year earlier, while agrochemicals recorded a Rs 6.82 lakh segment loss. Diagnostic kits generated Rs 24.42 crore of profit before interest and tax, against the group’s Rs 24.30 crore consolidated profit before tax.

How did 3B BlackBio Dx diagnostic kits perform in Q2?

3B BlackBio Dx’s diagnostic-kits segment recorded revenue of Rs 45.02 crore in the September 2026 quarter, compared with Rs 32.06 crore in the June 2026 quarter and Rs 30.43 crore in the September 2025 quarter. The segment contributed Rs 45.02 crore of the group’s Rs 48.28 crore revenue from operations, while agrochemicals contributed Rs 3.26 crore.

Diagnostic-kits segment profit before interest and tax increased to Rs 24.42 crore in Q2 from Rs 19.38 crore in the year-earlier quarter and Rs 13.33 crore in the preceding quarter. The segment incurred Rs 5.91 lakh of interest expense in the September 2026 quarter, compared with Rs 2.32 lakh a year earlier and Rs 10.22 lakh in June 2026.

For the half year ended September 30, 2026, diagnostic-kits revenue was Rs 77.08 crore, compared with Rs 50.39 crore in the corresponding 2025 period. Its profit before interest and tax was Rs 37.75 crore for the six months, compared with Rs 35.30 crore a year earlier, while the audited full-year segment profit for the year ended March 31, 2026 was Rs 77.07 crore.

What happened to 3B BlackBio Dx agrochemicals in Q2?

3B BlackBio Dx’s agrochemicals revenue declined to Rs 3.26 crore in the September 2026 quarter from Rs 3.47 crore in the September 2025 quarter, although it rose from Rs 1.43 crore in the June 2026 quarter. The segment moved to a Rs 6.82 lakh loss before interest and tax from a Rs 27.22 lakh profit a year earlier, after reporting a Rs 3,000 profit in the preceding quarter.

For the half year ended September 30, 2026, agrochemicals revenue fell to Rs 4.69 crore from Rs 5.75 crore in the corresponding prior-year period. The segment reported a Rs 6.18 lakh loss before interest and tax for the six months, compared with a Rs 22.86 lakh profit in the half year ended September 30, 2025.

3B BlackBio Dx states that its agrochemical business is seasonal and can be affected by weather conditions and cropping patterns. Agrochemicals incurred Rs 4,000 of interest expense in Q2, compared with Rs 1.27 lakh in the September 2025 quarter, and held Rs 27.96 crore of segment assets at September 30, 2026, versus Rs 27.91 crore a year earlier.

How did the segments shape 3B BlackBio Dx consolidated earnings?

3B BlackBio Dx reported consolidated revenue from operations of Rs 48.28 crore in the September 2026 quarter, up from Rs 33.90 crore a year earlier and Rs 33.49 crore in June 2026. Other income was Rs 4.71 crore, compared with Rs 5.51 crore in the September 2025 quarter and Rs 6.14 crore in the preceding quarter, taking total income to Rs 52.99 crore.

Consolidated profit before tax was Rs 24.30 crore in Q2, compared with Rs 19.62 crore in the year-earlier quarter and Rs 13.22 crore in the June 2026 quarter. The combined segment result before interest and tax was Rs 24.36 crore: diagnostic kits supplied Rs 24.42 crore, while the agrochemicals loss reduced that amount by Rs 6.82 lakh.

Consolidated profit after tax was Rs 18.02 crore in the September 2026 quarter, against Rs 15.04 crore a year earlier and Rs 8.98 crore in June 2026. For the half year ended September 30, 2026, revenue from operations reached Rs 81.77 crore from Rs 56.14 crore, while profit before tax increased to Rs 37.52 crore from Rs 35.48 crore.

Half-year profit after tax was Rs 27.00 crore, compared with Rs 27.68 crore in the corresponding 2025 period, despite the increase in profit before tax. Current tax expense was Rs 10.57 crore for the half year ended September 30, 2026, versus Rs 7.80 crore a year earlier; the filing presents the quarterly and half-year consolidated results as unaudited.

What do 3B BlackBio Dx segment assets and capital employed show?

3B BlackBio Dx’s diagnostic-kits segment had Rs 374.25 crore of assets at September 30, 2026, compared with Rs 359.13 crore at June 30, 2026 and Rs 312.92 crore a year earlier. Diagnostic-kits liabilities were Rs 44.98 crore at the September quarter-end, down from Rs 52.82 crore three months earlier but above Rs 34.43 crore at September 30, 2025.

Diagnostic-kits capital employed was Rs 329.27 crore at September 30, 2026, versus Rs 306.31 crore at June 30, 2026 and Rs 278.49 crore a year earlier. Agrochemicals capital employed was Rs 25.26 crore, compared with Rs 25.33 crore in June 2026 and Rs 25.47 crore at September 30, 2025, bringing total segment capital employed to Rs 354.53 crore.

The consolidated balance sheet reported total assets of Rs 402.22 crore at September 30, 2026, compared with Rs 378.00 crore at March 31, 2026. Trade receivables increased to Rs 64.25 crore from Rs 50.09 crore during that six-month period, while cash and cash equivalents decreased to Rs 33.99 crore from Rs 38.31 crore.

The consolidated results include subsidiaries TRUPCR Europe Limited and Coris Holding SRL, Belgium. The limited-review report says the subsidiaries’ unaudited interim financial results and other unaudited financial information were not material to the group, while total consolidated segment liabilities were Rs 47.68 crore at September 30, 2026.

Conclusion

The September 2026 segment disclosure shows that diagnostic kits accounted for Rs 45.02 crore of 3B BlackBio Dx’s Rs 48.28 crore quarterly operating revenue and generated Rs 24.42 crore of segment profit before interest and tax. Agrochemicals, by contrast, reported Rs 3.26 crore of revenue and a Rs 6.82 lakh loss, reducing the combined segment result.

The next reported period will show whether diagnostic-kits revenue can extend the Rs 77.08 crore recorded in the first half ended September 30, 2026 and whether agrochemicals can return to profit after its Rs 6.18 lakh first-half loss. Management identifies seasonality, weather conditions and cropping patterns as factors that can affect agrochemicals performance.